Nicholas M. Durham

4.4k total citations
30 papers, 1.5k citations indexed

About

Nicholas M. Durham is a scholar working on Oncology, Immunology and Genetics. According to data from OpenAlex, Nicholas M. Durham has authored 30 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 16 papers in Immunology and 7 papers in Genetics. Recurrent topics in Nicholas M. Durham's work include CAR-T cell therapy research (15 papers), Cancer Immunotherapy and Biomarkers (12 papers) and Immunotherapy and Immune Responses (10 papers). Nicholas M. Durham is often cited by papers focused on CAR-T cell therapy research (15 papers), Cancer Immunotherapy and Biomarkers (12 papers) and Immunotherapy and Immune Responses (10 papers). Nicholas M. Durham collaborates with scholars based in United States, United Kingdom and Netherlands. Nicholas M. Durham's co-authors include Charles G. Drake, Tullia C. Bruno, Derese Getnet, Christopher J. Nirschl, Christopher M. Jackson, Ching Ching Leow, Robert E. Hollingsworth, Joseph F. Grosso, Jonathan Rios‐Doria and Raymond Rothstein and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Nicholas M. Durham

26 papers receiving 1.5k citations

Peers

Nicholas M. Durham

IMMUN

ONCOL

GENET

PHYSI

Madhav V. Dhodapkar United States

Alessandra Dondero Italy

Willemijn Hobo Netherlands

Erietta Stelekati United States

Marie King Ireland

Loren D. Erickson United States

Tyler R. Simpson United States

Amparo Sempere Spain

Julie Ritchey United States

Kristin G. Anderson United States

Madhav V. Dhodapkar United States

Nicholas M. Durham

1.8k ×2.0

IMMUN

1.1k ×1.3

ONCOL

593 ×2.4

126 ×0.9

GENET

25 ×0.2

PHYSI

Citations per year, relative to Nicholas M. Durham Nicholas M. Durham (= 1×) peers Madhav V. Dhodapkar

Countries citing papers authored by Nicholas M. Durham

Since Specialization

Citations

This map shows the geographic impact of Nicholas M. Durham's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nicholas M. Durham with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nicholas M. Durham more than expected).

Fields of papers citing papers by Nicholas M. Durham

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nicholas M. Durham. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nicholas M. Durham. The network helps show where Nicholas M. Durham may publish in the future.

Co-authorship network of co-authors of Nicholas M. Durham

This figure shows the co-authorship network connecting the top 25 collaborators of Nicholas M. Durham. A scholar is included among the top collaborators of Nicholas M. Durham based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nicholas M. Durham. Nicholas M. Durham is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Willis, Sophie E., Chris G. Richardson, Andrew G. Chambers, et al.. (2024). CLDN18/CLDN18.2 IHC assay comparison (SP455, 43-14A, EPR19202) and co-prevalence expression with other biomarkers in gastric carcinoma.. Journal of Clinical Oncology. 42(16_suppl). 4089–4089. 1 indexed citations

Davar, Diwakar, Benedito A. Carneiro, Grace K. Dy, et al.. (2024). Phase I study of a recombinant attenuated oncolytic virus, MEDI5395 (NDV–GM-CSF), administered systemically in combination with durvalumab in patients with advanced solid tumors. Journal for ImmunoTherapy of Cancer. 12(11). e009336–e009336. 9 indexed citations

Shaw, Amanda Rosewell, Daisuke Morita, Caroline E. Porter, et al.. (2024). IL-12 encoding oNDV synergizes with CAR-T cells in orthotopic models of non-small cell lung cancer. PubMed. 32(4). 200899–200899.

Aggarwal, Charu, Nabil F. Saba, Alain P. Algazi, et al.. (2022). Safety and Efficacy of MEDI0457 plus Durvalumab in Patients with Human Papillomavirus–Associated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research. 29(3). 560–570. 26 indexed citations

Swanson, Phillip A., Marcelino Padilla, Kelly McGlinchey, et al.. (2021). AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein–specific T _H 1 response with a diverse TCR repertoire. Science Translational Medicine. 13(620). eabj7211–eabj7211. 59 indexed citations

Harper, James A., Shannon Burke, Jon Travers, et al.. (2021). Recombinant Newcastle Disease Virus Immunotherapy Drives Oncolytic Effects and Durable Systemic Antitumor Immunity. Molecular Cancer Therapeutics. 20(9). 1723–1734. 10 indexed citations

Si, Han, Todd Creasy, Koustubh Ranade, et al.. (2020). A New Pipeline to Predict and Confirm Tumor Neoantigens Predict Better Response to Immune Checkpoint Blockade. Molecular Cancer Research. 19(3). 498–506. 10 indexed citations

Balmanoukian, Ani Sarkis, Jeffrey R. Infante, Raid Aljumaily, et al.. (2020). Safety and Clinical Activity of MEDI1873, a Novel GITR Agonist, in Advanced Solid Tumors. Clinical Cancer Research. 26(23). 6196–6203. 40 indexed citations

Aggarwal, Charu, Nabil F. Saba, Alain P. Algazi, et al.. (2020). 916MO Safety and efficacy of MEDI0457 plus durvalumab in patients (pts) with human papillomavirus-associated recurrent/metastatic head and neck squamous cell carcinoma (HPV+ R/M HNSCC). Annals of Oncology. 31. S661–S662. 16 indexed citations

10.

Durham, Nicholas M., Kathy Mulgrew, Kelly McGlinchey, et al.. (2017). Oncolytic VSV Primes Differential Responses to Immuno-oncology Therapy. Molecular Therapy. 25(8). 1917–1932. 51 indexed citations

11.

Durham, Nicholas M., et al.. (2017). GITR ligand fusion protein agonist enhances the tumor antigen–specific CD8 T-cell response and leads to long-lasting memory. Journal for ImmunoTherapy of Cancer. 5(1). 47–47. 31 indexed citations

12.

Jackson, Christopher M., Christina M. Kochel, Christopher J. Nirschl, et al.. (2015). Systemic Tolerance Mediated by Melanoma Brain Tumors Is Reversible by Radiotherapy and Vaccination. Clinical Cancer Research. 22(5). 1161–1172. 54 indexed citations

13.

Rios‐Doria, Jonathan, Nicholas M. Durham, Leslie Wetzel, et al.. (2015). Doxil Synergizes with Cancer Immunotherapies to Enhance Antitumor Responses in Syngeneic Mouse Models. Neoplasia. 17(8). 661–670. 146 indexed citations

14.

Huang, Qihui, Nicholas M. Durham, Erin Sult, et al.. (2015). Abstract 1538: Levels and enzyme activity of CD73 in primary samples from cancer patients. Cancer Research. 75(15_Supplement). 1538–1538. 9 indexed citations

15.

Simons, Brian W., Nicholas M. Durham, Tullia C. Bruno, et al.. (2014). A human prostatic bacterial isolate alters the prostatic microenvironment and accelerates prostate cancer progression. The Journal of Pathology. 235(3). 478–489. 65 indexed citations

16.

Belcaid, Zineb, Jillian Phallen, Jing Zeng, et al.. (2014). Focal Radiation Therapy Combined with 4-1BB Activation and CTLA-4 Blockade Yields Long-Term Survival and a Protective Antigen-Specific Memory Response in a Murine Glioma Model. PLoS ONE. 9(7). e101764–e101764. 181 indexed citations

17.

Durham, Nicholas M., Christopher J. Nirschl, Christopher M. Jackson, et al.. (2014). Lymphocyte Activation Gene 3 (LAG-3) Modulates the Ability of CD4 T-cells to Be Suppressed In Vivo. PLoS ONE. 9(11). e109080–e109080. 143 indexed citations

18.

Wada, Satoshi, Christopher M. Jackson, Kiyoshi Yoshimura, et al.. (2013). Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer. Journal of Translational Medicine. 11(1). 89–89. 63 indexed citations

19.

Bruno, Tullia C., Joseph F. Grosso, Derese Getnet, et al.. (2011). Anti‐tumor effects of endogenous prostate cancer‐specific CD8 T cells in a murine TCR transgenic model. The Prostate. 72(5). 514–522. 9 indexed citations

20.

Getnet, Derese, Joseph F. Grosso, Monica V. Goldberg, et al.. (2010). A role for the transcription factor Helios in human CD4+CD25+ regulatory T cells. Molecular Immunology. 47(7-8). 1595–1600. 184 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact